Joint Formulary & PAD

Vardenafil - Erectile dysfunction combination therapy

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Not Specified
Associated Icons :
BNF SPC
NFD1
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Vardenafil
Indication :
Erectile dysfunction combination therapy
Group Name :
Keywords :
Phosphodiesterase type 5 inhibitors, ED, Impotence
Brand Names Include :
Levitra
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Vardenafil is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Erectile dysfunction combination therapy.

Committee Recommendations (1)

Use of both oral and non-oral combination treatments for erectile dysfunction in patients who had not responded or had a sub-optimal response to monotherapy was considered.The network members concurred that based on the limited available evidence, noting the feedback from clinicians, that combination treatments should not be supported and a BLACK status should be given on the PAD.Please see policy statement from June 2012